1. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
- Author
-
Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J, Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E, Fauchier, Laurent, Filippatos, Gerasimos, Kalman, Jonathan M, La Meir, Mark, Lane, Deirdre A, Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y H, Pinto, Fausto J, Thomas, G Neil, Valgimigli, Marco, Van Gelder, Isabelle C, Van Putte, Bart P, Watkins, Caroline L, Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J G M, Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Fitzsimons, Donna, Folliguet, Thierry, Gale, Chris P, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A, Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S, Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V, Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F E, Petersen, Steffen E, Piccini, Jonathan P, Popescu, Bogdan A, Pürerfellner, Helmut, Richter, Dimitrios J, Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B, Simpson, Iain A, Shlyakhto, Evgeny, Sinner, Moritz F, Steffel, Jan, Sousa-Uva, Miguel, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M, Neil Thomas, G, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiovascular Centre (CVC), Surgical clinical sciences, and Cardiac Surgery
- Subjects
left atrial ablation ,left atrial appendage occlusion ,AF surgery ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Management of atrial fibrillation ,030204 cardiovascular system & hematology ,Cardioversion ,VITAMIN-K ANTAGONIST ,surgery ,chemistry.chemical_compound ,0302 clinical medicine ,cardioversion ,Edoxaban ,QUALITY-OF-LIFE ,antiarrhythmic drugs ,OBSTRUCTIVE SLEEP-APNEA ,catheter ablation ,RADIOFREQUENCY CATHETER ABLATION ,Medicine ,atrial fibrillation ,030212 general & internal medicine ,anticoagulation ,reproductive and urinary physiology ,ComputingMilieux_MISCELLANEOUS ,pulmonary vein isolation ,0303 health sciences ,rhythm control ,EACTS ,HEART RHYTHM SOCIETY ,recommendations ,Atrial fibrillation ,General Medicine ,non-Vitamin K antagonist oral anticoagulants ,Vitamin K antagonist ,PULMONARY-VEIN ISOLATION ,stroke ,3. Good health ,2020 ESC Guidelines ,Dronedarone ,vitamin K antagonists ,Cardiothoracic surgery ,Cardio-Thoracic Surgery ,embryonic structures ,DIRECT ORAL ANTICOAGULANTS ,cardiovascular system ,Cardiology ,Dose reduction ,biological phenomena, cell phenomena, and immunity ,Cardiology and Cardiovascular Medicine ,medicine.drug ,Quinidine ,medicine.medical_specialty ,medicine.drug_class ,non-vitamin K antagonist oral anticoagulants ,PERCUTANEOUS CORONARY INTERVENTION ,Renal function ,macromolecular substances ,ABC pathway ,Guidelines ,rate control ,screening ,upstream therapy ,Vitamin K antagonists ,B700 ,03 medical and health sciences ,Internal medicine ,Diseases of the circulatory (Cardiovascular) system ,cardiovascular diseases ,030304 developmental biology ,urogenital system ,business.industry ,medicine.disease ,TRANSIENT ISCHEMIC ATTACK ,ANTIARRHYTHMIC-DRUG-THERAPY ,chemistry ,030228 respiratory system ,Concomitant ,RC666-701 ,business - Abstract
Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight
- Published
- 2021